BioTech

Spark Therapeutics (ONCE), a commercial gene therapy company, announced Friday that the European Commission has granted marketing authorization for LUXTURNA (voretigene neparvovec).

EAST HANOVER, N.J., May 24, 2019 /PRNewswire/ -- Novartis today announced the US Food and Drug Administration (FDA) has approved Piqray® (alpelisib

Sobi™ to Acquire Synagis® US Rights From AstraZeneca - Creates a Platform for Global Growth - read this article along with other careers information, tips and advice on BioSpace

Source: globenewswire.com Immunomedics Inc. has received a Complete Response Letter from the U.S. Food and Drug Administration (US FDA) for the Biologics License Application seeking...

Pfizer Inc. (NYSE: PFE) and GlaxoSmithKline plc (NYSE:GSK) today announced they have entered into an agreement to create a premier global consumer hea

Sun Pharma launches ready-to-infuse INFUGEM - the first and only chemotherapy product in a premixed, ready-to-infuse formulation - in the US.

DUBLIN, March 18, 2019 /PRNewswire/ -- Perrigo Company plc (NYSE; TASE: PRGO) a leading global provider of "Quality, Affordable, Self-Care Products™

FLIR Systems, Inc. (NASDAQ: FLIR) announced today that it has acquired Aeryon Labs Inc., a leading developer of high-performance unmanned aerial syste

Gilead Sciences Inc. (Nasdaq: GILD) and insitro announced today that the companies have entered into a strategic collaboration to discover and develop

Flu sufferers now have a new option for relieving symptoms. Xofluza (baloxavir marboxil), a single-dose, oral prescription drug, was approved by the US Food and Drug Administration on Wednesday. The antiviral is the first new flu treatment approved by the FDA in nearly 20 years, said FDA Commissioner Dr. Scott Gottlieb in a statement.